Clinical Safety

Proposed revisions to human subject protections aim to ease the regulatory load on learning health systems while introducing more practical exemptions for low-risk research categories. The Department of Health and Human Services (DHHS) recently unveiled a comprehensive Unified Agenda that signals a

The focus of the next five-year regulatory cycle is shifting toward a model where pharmaceutical companies must meet strict timelines for filing safety reports after a drug is approved. As the 2026 negotiations between the United States Food and Drug Administration and the pharmaceutical industry

By combining the sexual wellness line Woodwork with Freddie’s clinical capabilities, Grindr is building an end-to-end medical infrastructure for its members. This move represents a profound shift from a platform once characterized primarily by social interaction into a comprehensive healthcare

Establishing safety benchmarks through single-patient trials allows clinicians to determine which disease mechanisms are most susceptible to targeted antisense oligonucleotide interventions. The fight against amyotrophic lateral sclerosis (ALS) has reached a new milestone through a landmark

The pharmaceutical industry has shifted toward multi-parameter optimization, testing every new molecular version for solubility and stability alongside its primary biological activity. This fundamental change marks the transition from simple screening to a highly disciplined engineering phase where

Addressing the risk of sarcopenia in patients using GLP-1 therapies has become a primary objective for researchers developing next-generation metabolic interventions. As the global pharmaceutical industry experiences a seismic shift toward metabolic health, the focus has broadened from achieving